

Andrea Baran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6212257/publications.pdf>

Version: 2024-02-01

66
papers

1,116
citations

516710

16
h-index

414414

32
g-index

69
all docs

69
docs citations

69
times ranked

2374
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia. <i>Leukemia Research</i> , 2022, 112, 106749.	0.8	5
2	Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 327-327.	1.6	1
3	The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact. <i>Haematologica</i> , 2022, 107, 1460-1465.	3.5	2
4	Evaluating Age as a Predictor of Postoperative Opioid Use and Prescribing Habits in Older Adults With Cancer. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 678-683.e1.	2.5	5
5	Gene Expression Risk Scores for COVID-19 Illness Severity. , 2022, , .		0
6	Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 598-605.	1.3	1
7	Targeted therapy for treatment of patients with classical hairy cell leukemia. <i>Leukemia Research</i> , 2021, 102, 106522.	0.8	5
8	Risk of second cancer among young prostate cancer survivors. <i>Radiation Oncology Journal</i> , 2021, 39, 91-98.	1.5	5
9	Characterizing Naked Nuclei Frequency and Movement in Primary AML Cell Culture Using an ECM-Based Model. <i>Blood</i> , 2021, 138, 2365-2365.	1.4	0
10	Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 2640-2640.	1.4	0
11	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. <i>Journal of the National Cancer Institute</i> , 2020, 112, 179-190.	6.3	71
12	Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy. <i>American Journal of Hematology</i> , 2020, 95, E16-E18.	4.1	2
13	A Multicentered Academic Medical Center Experience of a Simulated Root Cause Analysis (RCA) for Hematology/Oncology Fellows. <i>Journal of Cancer Education</i> , 2020, , 1.	1.3	3
14	Non-donor specific anti-human leukocyte antigen (HLA) antibodies are not associated with poor outcome in hematopoietic stem cell transplant recipients. <i>Human Immunology</i> , 2020, 81, 407-412.	2.4	1
15	Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience. <i>Clinical Colorectal Cancer</i> , 2020, 19, e124-e128.	2.3	2
16	Building a High-Dose-Rate Prostate Brachytherapy Program With Real-Time Ultrasound-Based Planning: Initial Safety, Quality, and Outcome Results. <i>Advances in Radiation Oncology</i> , 2020, 5, 388-395.	1.2	2
17	Initial treatment of Bâ€cell polymphocytic leukemia with ibrutinib. <i>American Journal of Hematology</i> , 2020, 95, E108-E110.	4.1	8
18	Lymphocyte-Specific Biomarkers Associated With Preterm Birth and Bronchopulmonary Dysplasia. <i>Frontiers in Immunology</i> , 2020, 11, 563473.	4.8	13

#	ARTICLE	IF	CITATIONS
19	A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 41-42.	1.4	6
20	Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells. <i>Blood</i> , 2020, 136, 45-45.	1.4	4
21	A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 5-6.	1.4	4
22	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 41-42.	1.4	0
23	Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2020, 136, 20-21.	1.4	1
24	Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation. <i>Leukemia and Lymphoma</i> , 2019, 60, 3569-3572.	1.3	4
25	Systematic Review of Randomized Controlled Trials of Exercise Interventions Using Digital Activity Trackers in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 57-63.	4.9	50
26	Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1713-1719.	2.0	7
27	Evaluation of the clinical impact of concomitant acid suppression therapy in colorectal cancer patients treated with capecitabine monotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1839-1845.	0.9	14
28	Host Gene Expression in Nose and Blood for the Diagnosis of Viral Respiratory Infection. <i>Journal of Infectious Diseases</i> , 2019, 219, 1151-1161.	4.0	43
29	Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment. <i>Annals of Hematology</i> , 2019, 98, 481-489.	1.8	7
30	Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 41-47.	0.4	19
31	Surveillance for locally advanced esophageal and gastroesophageal junction (GEJ) cancers: Patterns of recurrence and methods of detection.. <i>Journal of Clinical Oncology</i> , 2019, 37, 32-32.	1.6	1
32	Genetic testing patterns for homologous recombination repair (HRR) alterations in patients with metastatic prostate cancer (mPC): An assessment at the University of Rochester (UR).. <i>Journal of Clinical Oncology</i> , 2019, 37, 322-322.	1.6	0
33	Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7547-7547.	1.6	0
34	High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, e19058-e19058.	1.6	0
35	The impact of method of recurrence detection on esophageal/gastroesophageal junction (EGJ) cancer outcomes.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15580-e15580.	1.6	0
36	Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. <i>Leukemia and Lymphoma</i> , 2018, 59, 625-632.	1.3	57

#	ARTICLE	IF	CITATIONS
37	Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 781-787.	0.4	8
38	Management of melanoma in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2018, 71, 43-46.	0.8	17
39	Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. <i>Cancer Immunology Research</i> , 2018, 6, 1150-1160.	3.4	57
40	T cell developmental arrest in former premature infants increases risk of respiratory morbidity later in infancy. <i>JCI Insight</i> , 2018, 3, .	5.0	34
41	Nonoperative management of locally advanced esophageal and junctional (GEJ) cancers: The University of Rochester experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, 144-144.	1.6	0
42	Immunotherapy use, outcomes, and toxicities in gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 100-100.	1.6	0
43	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017, 151, 89-95.	1.7	109
44	Transcriptomic Biomarkers to Discriminate Bacterial from Nonbacterial Infection in Adults Hospitalized with Respiratory Illness. <i>Scientific Reports</i> , 2017, 7, 6548.	3.3	54
45	HIGH-RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA ARE NOT ENROLLED ON CLINICAL TRIALS. <i>Hematological Oncology</i> , 2017, 35, 181-182.	1.7	0
46	HIGH RATE OF MORBID CENTRAL LINE ASSOCIATED COMPLICATIONS DURING TREATMENT WITH DOSE-ADJUSTED R-EPOCH THERAPY FOR NON-HODGKIN LYMPHOMA. <i>Hematological Oncology</i> , 2017, 35, 413-414.	1.7	0
47	Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer. <i>PLoS ONE</i> , 2017, 12, e0189410.	2.5	11
48	Central line-associated complications during treatment with DA-R-EPOCH therapy for NHL.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7543-7543.	1.6	1
49	Enrollment of high-risk patients with diffuse large B-cell lymphoma in clinical trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6536-6536.	1.6	0
50	Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial. <i>PLoS ONE</i> , 2016, 11, e0152986.	2.5	19
51	Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 322-328.e2.	0.4	5
52	Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. <i>Cancer Medicine</i> , 2016, 5, 3059-3067.	2.8	18
53	Fast Nonparametric Density-Based Clustering of Large Datasets Using a Stochastic Approximation Mean-Shift Algorithm. <i>Journal of Computational and Graphical Statistics</i> , 2016, 25, 899-916.	1.7	4
54	Implementation of a penicillin allergy screening tool to optimize aztreonam use. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 298-306.	1.0	33

#	ARTICLE	IF	CITATIONS
55	The role of myeloid derived suppressor cells in cholangiocarcinoma: A potential target for therapy.. Journal of Clinical Oncology, 2016, 34, 273-273.	1.6	4
56	Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. PLoS ONE, 2016, 11, e0155503.	2.5	7
57	Biopsychosocial distress screening using the National Comprehensive Cancer Network (NCCN) distress thermometer (DT) and patient reported outcome measurement information system (PROMIS) in an academic genitourinary (GU) medical oncology practice.. Journal of Clinical Oncology, 2016, 34, 350-350.	1.6	0
58	Should clinical case definitions of influenza in hospitalized older adults include fever?. Influenza and Other Respiratory Viruses, 2015, 9, 23-29.	3.4	53
59	Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial. Journal of Infectious Diseases, 2015, 212, 1692-1700.	4.0	103
60	Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. British Journal of Cancer, 2014, 111, 430-436.	6.4	56
61	Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood, 2014, 124, 1259-1265.	1.4	34
62	Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival. Blood, 2014, 124, 3984-3984.	1.4	1
63	Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Lymphoma. Blood, 2014, 124, 1746-1746.	1.4	0
64	Can serum procalcitonin levels help interpret indeterminate chest radiographs in patients hospitalized with acute respiratory illness?. Journal of Hospital Medicine, 2013, 8, 61-67.	1.4	9
65	Bacterial Complications of Respiratory Tract Viral Illness: A Comprehensive Evaluation. Journal of Infectious Diseases, 2013, 208, 432-441.	4.0	127
66	Factors associated with symptomatic rhinovirus infection in patients with COPD. Journal of Clinical Virology, 2012, 55, 343-347.	3.1	8